India's Natco Pharma jumps after launching ovarian cancer drug in US
BUZZ-India's Natco Pharma jumps after launching ovarian cancer drug in US ** Drug maker Natco Pharma NATP.NS shares rise as much as 3.15% to 809.8 rupees, its biggest intraday rise in two months
** Uptick after NATP announces the launch of carboplatin injection, a generic version of Paraplatin used to treat advanced ovarian cancer, in the US
** Co is launching the drug in a manufacturing collaboration with Chennai-based Teyro Labs
** NATP says it launched the drug to help address a critical shortage of the product in the US market
** Carboplatin injection had estimated sales of $27.8 million in the US for the 12 months ending June 2026, according to industry sales data, the co says
** NATP down 10.2% YTD, lagging a 12.8% rise in the pharma index .NIPHARM, according to exchange data
(Reporting by Bharath Rajeswaran in Bengaluru)
((bharath.rajeswaran@thomsonreuters.com; +91 9769003463;))
Recent news on Natco Pharma
See all newsBrief: Natco Pharma Launches Carboplatin Injection In Us With Teyro Labs
India's Natco Pharma jumps after launching ovarian cancer drug in US
Brief: Natco Pharma Announces Launch Of Carboplatin Injection In The U.S. Market
Brief: Natco Pharma To Increase Its Investment In Egenesis To $16.70 Million
Brief: Natco Pharma Approves Rights Issue Up To 12.79 Billion Rupees